Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

eFFECTOR Therapeutics, Inc. EFTR

Healthcare  —  Biotechnology
0.00 0.00 NaN as of 25 Sep
Market cap
$200.0K
P/E
0.0×
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

eFFECTOR Therapeutics, Inc. (EFTR) Business Profile

Updated before January 2025

Company Overview

eFFECTOR Therapeutics, Inc. (EFTR) is a clinical-stage biopharmaceutical company dedicated to pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer and other serious diseases. Founded in 2012, the company is headquartered in San Diego, California. EFTR was co-founded by Dr. Kevan Shokat and Dr. Gerald Crabtree, two prominent scientists in the field of translational control biology. The company is led by a seasoned executive team, including Steve Worland, Ph.D., who serves as the President and Chief Executive Officer. Dr. Worland brings decades of experience in drug discovery and development, having held leadership roles at companies like Pfizer and Anadys Pharmaceuticals.

EFTR’s mission is to harness the power of translational control to develop innovative therapies that address unmet medical needs. The company’s proprietary platform focuses on modulating the process by which cells produce proteins, a critical mechanism in disease progression, particularly in cancer.

Core Business Segments

EFTR’s business revolves around its proprietary STRI platform, which is designed to selectively regulate the translation of messenger RNA (mRNA) into proteins. This approach enables the company to target disease-driving proteins while minimizing off-target effects. The company’s core business segments include:

1. Oncology Therapeutics

EFTR’s primary focus is on developing therapies for cancer. Its lead product candidates include:

  • Zotatifin (eFT226): A small molecule inhibitor of eIF4A, a key component of the translation initiation complex. Zotatifin is being developed for the treatment of solid tumors, including breast cancer and non-small cell lung cancer (NSCLC). It is currently in Phase 2 clinical trials.

  • eFT508 (Tomivosertib): An inhibitor of MNK1 and MNK2, enzymes that regulate the translation of oncogenic proteins. Tomivosertib is being evaluated in combination with immune checkpoint inhibitors for the treatment of advanced solid tumors.

2. Immuno-Oncology

EFTR is also exploring the potential of STRIs in enhancing the efficacy of immunotherapies. By targeting specific pathways involved in immune evasion, the company aims to improve patient outcomes in cancers that are resistant to current treatments.

3. Research Collaborations

EFTR collaborates with academic institutions and pharmaceutical companies to expand the applications of its STRI platform. These partnerships enable the company to explore new therapeutic areas and accelerate the development of its pipeline.

Business Model

EFTR operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Licensing Agreements: EFTR licenses its STRI technology to pharmaceutical companies for the development of therapies in areas outside its core focus.
  • Collaborative Research: The company partners with academic institutions and biotech firms to co-develop new applications for its platform.
  • Clinical Milestones and Royalties: EFTR earns milestone payments and royalties from its partners as its therapies progress through clinical development and commercialization.

This diversified approach allows EFTR to mitigate risks while maximizing the potential of its innovative platform.

Strategic Direction

EFTR is committed to advancing its pipeline of STRI-based therapies and expanding its platform’s applications. Key strategic priorities include:

  • Pipeline Expansion: The company plans to initiate additional clinical trials for Zotatifin and Tomivosertib in new indications, such as hematologic malignancies and rare cancers.
  • Global Partnerships: EFTR aims to establish collaborations with international pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: The company is exploring ways to minimize its environmental footprint by adopting sustainable practices in its research and manufacturing processes.
  • New Product Categories: EFTR is investigating the potential of STRIs in non-oncology indications, such as neurodegenerative diseases and viral infections.

Competitive Landscape

EFTR operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Moderna, Inc.: Known for its mRNA-based therapies, Moderna competes with EFTR in the field of translational control.
  • BioNTech SE: Another leader in mRNA technology, BioNTech is exploring applications in oncology and infectious diseases.
  • Arvinas, Inc.: Specializes in targeted protein degradation, a complementary approach to EFTR’s STRI platform.
  • Mirati Therapeutics, Inc.: Focuses on targeted cancer therapies, including KRAS inhibitors.

Despite the competition, EFTR’s unique focus on STRIs gives it a competitive edge in targeting disease-driving proteins with high specificity.

Risk Factors

EFTR faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of EFTR’s therapies depends on positive clinical trial outcomes, which are inherently uncertain.
  • Regulatory Challenges: The company must navigate complex regulatory pathways to bring its products to market.
  • Market Dependence: EFTR’s revenue is heavily reliant on the success of its lead product candidates.
  • Supply Chain Disruptions: Delays in the supply of raw materials or manufacturing issues could hinder the development of its therapies.
  • Competitive Pressure: The biopharmaceutical industry is highly competitive, with rapid advancements in technology and new entrants.

Recent Developments

EFTR has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase 2 trial of Zotatifin in patients with ER-positive breast cancer.
  • Partnerships: EFTR entered into a collaboration with a leading pharmaceutical company to explore the use of STRIs in rare genetic disorders.
  • Corporate Milestones: The company successfully raised additional capital through a public offering, strengthening its financial position.

Global developments, such as the COVID-19 pandemic, have underscored the importance of innovative therapies, further validating EFTR’s approach.

Investment Considerations

Investors considering EFTR should weigh the following factors:

Strengths

  • Innovative Platform: EFTR’s STRI technology represents a novel approach to drug development.
  • Strong Pipeline: The company has multiple product candidates in clinical development.
  • Experienced Leadership: EFTR’s management team has a proven track record in the biopharmaceutical industry.

Risks

  • Early-Stage Company: As a clinical-stage company, EFTR has yet to generate significant revenue.
  • Regulatory and Clinical Risks: The success of its therapies depends on regulatory approvals and clinical trial outcomes.
  • Market Volatility: The biopharmaceutical sector is subject to high market volatility, which could impact EFTR’s stock price.

Conclusion

eFFECTOR Therapeutics, Inc. is at the forefront of translational control biology, leveraging its proprietary STRI platform to develop innovative therapies for cancer and other serious diseases. While the company faces inherent risks as a clinical-stage biopharmaceutical firm, its strong pipeline, experienced leadership, and strategic partnerships position it for long-term success. As EFTR continues to advance its therapies and expand its platform’s applications, it remains a compelling player in the biopharmaceutical industry with significant growth potential.